SH3GL2 and laryngeal carcinoma: Increasing evidence shows that SH3GL2 is less expressed in a variety of carcinomas, including breast carcinoma 14, non‐small cell lung cancer 15, laryngeal carcinoma 16, urothelial carcinoma 17, and head and neck squamous cell carcinoma 18.